论文信息 - Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis. - 字舞流文

Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis.

W. Cai | G. Harris | A. Muzikansky | M. Bredella | V. Mautner | S. Plotkin | A. Kassarjian | V. Merker | J. Walker | M. Smith | S. Esparza

[1] M. Askenazi,et al. Quantitative Assessment of Whole-Body Tumor Burden in Adult Patients with Neurofibromatosis , 2012, PloS one.

[2] S. Mundlos,et al. MIA is a potential biomarker for tumour load in neurofibromatosis type 1 , 2011, BMC medicine.

[3] P. Worley,et al. Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin , 2010, Clinical Cancer Research.

[4] J. Bazarian,et al. Validation of serum markers for blood-brain barrier disruption in traumatic brain injury. , 2009, Journal of neurotrauma.

[5] E. Bastiaannet,et al. S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients , 2009, Annals of Surgical Oncology.

[6] G. Page,et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene , 2009, EMBO molecular medicine.

[7] P. Mazzone,et al. S100beta as a predictor of brain metastases: brain versus cerebrovascular damage. , 2005, Cancer.

[8] D. Evans,et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2 , 2005, Journal of Medical Genetics.

[9] A. Kanner,et al. Serum S100β , 2003, Cancer.

[10] Flávio Kapczinski,et al. The serum S100B concentration is age dependent. , 2002, Clinical chemistry.